Navigating Telemedicine and Pharmaceutical Policies Post-Pandemic

This chapter examines the evolution of telemedicine in the wake of the COVID-19 pandemic, focusing on the DEA's approach to accessibility and affordability. It also explores the implications of FDA policies on GLP-1 drugs and offers a controversial perspective on compounded medications amidst ethical challenges.